Thrombin-antithrombin III and D-dimer plasma levels in patients with benign or malignant ovarian tumours.
In 50 patients with benign ovarian tumours, 39 malignant ovarian carcinoma patients and 39 age-matched healthy women, plasma levels of thrombin-antithrombin III complex and D-dimer were determined as well as CA 125. The coagulation activation marker thrombin-antithrombin III complex and D-dimer levels were elevated in the malignant group compared to the benign and control groups. The results suggest that coagulation and fibrinolysis must play a prominent role in ovarian cancer. Moreover, D-dimer and thrombin-antithrombin III were equally useful as CA 125 for the discrimination of patients with benign or malignant ovarian tumours as evidenced by receiver operating and likelihood ratio calculations.
den Ouden
M
M
Department of Gynaecology, Atrium Medical Centre, Heerlen, The Netherlands.
Ubachs
J M
JM
Stoot
J E
JE
van Wersch
J W
JW
D000230:Adenocarcinoma / Q000097:blood / Q000276:immunology; D000232:Adenofibroma / Q000097:blood / Q000276:immunology; D000368:Aged; D000990:Antithrombin III / Q000378:metabolism*; D014408:Biomarkers, Tumor / Q000097:blood; D001777:Blood Coagulation; D018394:CA-125 Antigen / Q000097:blood; D016022:Case-Control Studies; D003537:Cystadenoma / Q000097:blood / Q000276:immunology; D005260:Female; D005338:Fibrin Fibrinogen Degradation Products / Q000378:metabolism*; D005342:Fibrinolysis; D006801:Humans; D016013:Likelihood Functions; D008875:Middle Aged; D010048:Ovarian Cysts / Q000097:blood / Q000276:immunology; D010051:Ovarian Neoplasms / Q000097:blood* / Q000276:immunology; D010447:Peptide Hydrolases / Q000378:metabolism*; D012372:ROC Curve
D014408:Biomarkers, Tumor; D018394:CA-125 Antigen; D005338:Fibrin Fibrinogen Degradation Products; C046193:antithrombin III-protease complex; C036309:fibrin fragment D; D000990:Antithrombin III; D010447:Peptide Hydrolases